43 of 44 Patients Achieved Sustained Virologic Response (SVR) | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Key Findings About HCV Genotype 3

Back to News Homepage
Next

Free Hepatitis C Webinar: Treatment Options and the Patient Experience

43 of 44 Patients Achieved Sustained Virologic Response (SVR)

The Editors at Hepatitis Central
April 23, 2014

Print this page

In a Phase II study conducted by Merck & Co, a 98% cure rate was achieved for previously untreated Hepatitis C patients without cirrhosis.

Merck hepatitis C drugs shine in easier to treat patients: study

By Bill Berkrot

Apr 10, 2014

(Reuters) – A two-drug combination being tested by Merck & Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.

Results of the study called C-Worthy were presented on Thursday at the annual meeting of the European Association for the Study of the Liver (EASL) in London. Researchers are due on Friday to present results of how the Merck pills fared in more difficult to treat patients, such as those who failed to be helped by prior treatments and those with more advanced liver disease.

Continue reading this entire article:
http://www.reuters.com/article/2014/04/10/us-hepatitis-merck-idUSBREA390B120140410

4 Comments
Share
Share
Previous

Key Findings About HCV Genotype 3

Back to News Homepage
Next

Free Hepatitis C Webinar: Treatment Options and the Patient Experience

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.